Diabetes Care

Dapagliflozin vs Empagliflozin: Uses, Differences and Monitoring

A comparison of two SGLT2 inhibitors and the questions that matter when reading a prescription.

By Global Medicines ExportUpdated: Educational article

Reference table

Key differences at a glance

US reference label comparison

QuestionFARXIGA (dapagliflozin)JARDIANCE (empagliflozin)
Tablet presentations5 mg and 10 mg10 mg and 25 mg
Adult heart failureLowers risk of cardiovascular death and hospital or urgent visits for heart failureLowers risk of cardiovascular death and hospitalisation for heart failure
Another adult cardiovascular indicationLowers risk of heart failure hospitalisation in selected adults with type 2 diabetesLowers risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease

Where the medicines overlap

Dapagliflozin and empagliflozin both block a protein called SGLT2 in the kidneys. This helps more glucose leave through the urine. The named US labels include use to improve glucose control in type 2 diabetes. Both also describe separate adult indications for heart failure and for chronic kidney disease at risk of progression.

One person may take the medicine to help manage blood glucose. Another may take it because the heart failure team wants to reduce the chance of a hospital stay. Ask which outcome your team will follow.

Compare the named US reference labels

Both labels have indications for glucose control in adults and children aged 10 and older with type 2 diabetes. Other indications, limitations and kidney function rules differ. The table describes US reference products.

Ask which kidney function rule applies

An estimated kidney filtration rate, or eGFR, helps the prescriber decide whether a particular product is suitable. A restriction that applies when a drug is used for glucose control need not apply when it is prescribed for a heart or kidney indication. Exact limits depend on the product and its label.

Bring recent test results and a full medicine list to a review. Include diuretics, insulin and other medicines that may lower blood sugar. Ask what follow-up tests are needed.

Review the safety questions

Both labels describe dehydration, genital and urinary infections, and diabetic ketoacidosis. Ketoacidosis can develop even without a markedly high blood sugar reading. Vomiting, abdominal pain or difficulty breathing while taking an SGLT2 inhibitor warrant urgent medical assessment, especially during illness or reduced food intake.

Make a plan with the prescriber or surgical team before a procedure that involves fasting. Ask when to pause and restart your medicine and how to manage any other diabetes treatment.

Read the two kidney trials in the context of your own results

DAPA-CKD studied dapagliflozin in people with chronic kidney disease and raised urine albumin. EMPA-KIDNEY studied empagliflozin under different entry criteria and included some participants with lower levels of urine albumin. Each trial compared one medicine with placebo and used its own definitions and follow-up. The two studies therefore cannot rank the medicines through a direct comparison.

Find your most recent eGFR and urine albumin-to-creatinine ratio, if one has been done. The guide to eGFR and urine ACR explains why clinicians may use both. Ask your care team how your underlying kidney condition, local product information and current treatment goals affect which study findings are most relevant to you.

Give the clinician context for a kidney result that changes

An early, reversible drop in eGFR can occur after starting an SGLT2 inhibitor. KDIGO guidance says the expected initial change generally does not require stopping treatment. The clinician can compare the timing and size of the change against your previous results. A continued decline or an unexpected change during illness deserves separate assessment.

Tell the clinician when the medicine was started, whether your water tablets or other medicines changed around the same time and whether you have had vomiting, diarrhea or poor intake. Ask who will review any repeat test and when you should call. If you feel faint or cannot keep fluids down, contact your care team promptly.

Match the listed product to the prescription

Dapagliflozin 10 mg Tablets and Empagliflozin 10 mg Tablets are separate catalogue presentations. Check the actual ingredient, manufacturer and local leaflet with your pharmacist. A tablet that combines several ingredients needs its own check.

The US FDA announcement of the first dapagliflozin generics identifies a narrower set of indications than the full FARXIGA label. Check the specific local product information before applying any label comparison.

Export product support

Need product, pack, and documentation details?

Global Medicines Export can support international B2B enquiries for product availability, strengths, pack information, quotation coordination, and shipment documentation review.

Common questions

Can I swap one 10 mg tablet for another?

They contain different active ingredients. Ask the prescriber to assess any change.

Why mention insulin to the prescriber?

Combining an SGLT2 inhibitor with insulin or certain other medicines may increase the chance of low blood glucose.

Do I need diabetes for a heart failure indication?

The adult heart failure indications in the named US labels do not require diabetes.

Which kidney result should I bring?

Bring the report with the eGFR, units and test date and any earlier results you have.

Can I tell which drug is better by comparing percentages from the two kidney trials?

The two trials enrolled different groups and used different outcome definitions. Ask which evidence applies to your kidney condition and treatment goal.

Can a single lower eGFR tell me my kidney disease is progressing faster?

One result needs context. Share the dates and values of prior tests, medication changes and recent illness so the clinician can interpret the trend and decide whether to repeat the test.

Important medical note

This article is for general educational information only. It is not medical advice, diagnosis, or a treatment plan. Medicines should be used only under the guidance of a qualified healthcare professional. Product availability, export documentation, and quotation support do not imply that a medicine is appropriate for any individual patient.

References